Kornimate/medical-research-clean huggingface dataset:
pilboutox® project: button battery poisoning from data collected by french poison control centres

Conditions: Button Battery Poisoning

Summary: button batteries are found in all householders and can be responsible for poisoning, in particular in children. unexpected complications and death in children who have ingested button battery have been published for over twenty years in medical literature. there are many questions related to the treatment that remain unanswered, because some data are missing in previously published studies. the main objective of this study is to precisely describe poisoning cases by button battery in order to propose a better management

button batteries are found in all householders and can be responsible for poisoning, in particular in children. unexpected complications and death in children who have ingested button battery have been published for over twenty years in medical literature. the most serious cases are those related to the ingestion of button cells, especially in children, when the battery gets stuck in the esophagus. poison control centres, as well as addictovigilance centres, are regularly called upon for serious poisoning resulting in hospitalization, for which precisely description is most often missing or difficult to obtain and limits the efficiency of the management of these poisonings. so there are many questions related to the treatment that remain unanswered, because some data are missing in previously published studies. for example, in many cases, there is a lack of detail of initial symptoms, delays between symptoms and completion of further tests, follow-ups... a prospective and descriptive study about button battery poisoning performed on data collected by french pcc will be conducted between the 1st june of 2016 and the 31 may of 2018: any call in a pcc that occurred during the period studied and concerning an exposure to a button cell regardless of the route of exposure, the age of the patient, and its symptomatology will be included. the following data will be taken : severe complication, need for surgery, length of hospital stay, death, risk factors concerning the battery (size, voltage), abnormalities at the first fibroscopy.

Eligibility criteria:
inclusion criteria: any call that occurred during the period studied in a poison control centre and concerning an exposure to a button cell regardless of the route of exposure, the age of the patient, and its symptomatology. exclusion criteria: animal cases

Keywords: button battery intoxication oesophageal necrosis poison control centre poisoning
bfr training on muscle morphology

Conditions: Blood Flow Restriction Training; Eccentric Training; Muscle Morphology; Patellofemoral Pain Syndrome; Anterior Cruciate Ligament Injuries

Summary: this randomized clinical trial study compares high-load eccentric training (hl-et), sham ll-bfrt, and low-load blood flow restriction (ll-bfrt) in sportsmen. the primary inquiries it seeks to address are: is ll-bfr superior to hl-et and sham ll-bfrt in terms of improving muscle morphology? is ll-bfr a more effective patellofemoral pain syndrome and acl injury preventive than hl-et and sham ll-bfrt? the three intervention groups that will be randomly assigned to participants are ll-bfrt, sham ll-bfrt, and hl-et. participants are expected to carry out: participants in ll-bfrt will be required to perform ll eccentric training at 30% of their repetition maximum (rm) and 70% of their artery occlusion pressure (aop). this training will include stairs, single leg squat, and single leg deadlift. participants in hl-et will be required to perform ll eccentric training at 70% of their maximum number of repetitions (rm). in order to determine whether muscular morphology and the prevention of patellofemoral pain syndrome and acl injury improve following the interventions and follow-up, researchers will compare ll-bfrt, sham ll-bfrt, and hl-et.


Eligibility criteria:
inclusion criteria: * being between the ages of 15 and 35 * play level 1 sports (fight martial arts, basketball, futsal, and soccer) at least twice a week * never experienced an patellofemoral pain syndrome or acl injury before * never experienced a grade iii sprain or strain * consent to participate in the study until its conclusion and provide informed consent. exclusion criteria: * having a tumor, cancer, vena thromboembolic disease, obesity, diabetes, hypertension, anemia, and renal failure * disabilities or those who are disabled.
outcomes of unfit patients with cll included in the gimema llc1114 trial who discontinued ibrutinib due to reasons other than disease progression

Conditions: Chronic Lymphocytic Leukemia

Summary: the goal of this observational study is to assess in the cohort of cll patients enrolled in the front-line gimema llc1114 study who discontinued ibrutinib the time to subsequent treatment. the main question it aims to answer is: • the 12 and 24-month ttnt measured from the time of ibrutinib discontinuation due to reasons other than cll progression, richter syndrome, malignancy or death, or lost to the follow-up. participants will be observed for the duration of the study.

this is an observational, multicenter, retrospective and prospective study aimed at analyzing in the cohort of cll patients enrolled in the front-line gimema llc1114 study the time to next treatment in patients who discontinued ibrutinib due to reasons other than cll progression, richter syndrome, malignancy or death, or lost to the follow-up.

Eligibility criteria:
inclusion criteria: * patients treated with ibrutinib included in the llc1114 gimema study who have discontinued ibrutinib after completing 78-months of treatment per protocol or patients treated with ibrutinib included in the llc1114 gimema study who were treated for at least 12 months before discontinuing ibrutinib due to reasons other than cll progression, richter syndrome, malignancy or death, or lost to the follow-up and had achieved a response (cr or pr/pr-l) lasting at least 6 months before discontinuing ibrutinib * informed consent, if applicable. exclusion criteria: - patients with concomitant conditions that may interfere with an appropriate assessment of the ttnt in the physician opinion.
insulin resistance in severely obese patients

Conditions: Obesity; Insulin Resistance; Diabetes

Summary: this study aims to understand the biological processes that link obesity to diseases including insulin resistance and diabetes. our approach involves studying the health of patient undergoing weight loss either via weight reduction surgery or by medically supervised liquid formula diets. patients must be enrolled in a weight treatment program at emory bariatrics, emory university, atlanta ga, to be eligible for this study. this study does not cover the cost of treatment at emory bariatrics. the hypothesis is that decreases in adipose-tissue derived factors during weight loss will be related to improvement in insulin function.

severe obesity affects 4.7% of the u.s. population. a significant number of these individuals suffer from impaired glucose tolerance and type ii diabetes due to insulin resistance (ir). although it is generally accepted that the accumulation of intraabdominal (ia) fat increases the risk of developing ir, the mechanisms responsible for this phenomenon are not yet understood. in addition, the role of subcutaneous (sc) fat towards the etiology of ir - protective, inert or detrimental - is still under debate. this is because sc adipose tissue releases adipocytokines (il-6, leptin, tnf- ) that have been demonstrated to impair insulin action. in individuals who are severely obese, hyperinsulinemia may induce an exaggerated production of adipocytokines from ia compared to sc fat stores. our specific aims are: (1) to determine relative contribution of abdominal sc fat versus ia fat to systemic levels of il-6, leptin and tnf- in lean and in severely obese individuals; (2) to determine the effects of systemic adipocytokine concentrations on whole body as well as tissue sensitivity to insulin. hypothesis: (a) in the context of severe obesity, ia fat produces increased quantities of il-6, leptin and tnf- compared to sc fat; (b) in severely obese patients undergoing weight loss, whole body and tissue ir can be predicted by changes in systemic adipocytokines. methods: adipose tissue content of il-6, leptin and tnf- will be determined by elisa in biopsies obtained from ia and sc fat stores in lean and severely obese patients. computer tomography-determined areas of ia and sc fat will be related to changes in systemic adipocytokines at baseline and 6-mo following weight loss therapy. changes in systemic il-6, leptin and tnf- will be assessed from measurements made at baseline and following 6-mo weight loss. for this time period we will also determine changes in whole body (via ivgtt) and tissue sensitivity to insulin (via glucose uptake into muscle and fat). relationships between systemic adipocytokines and ir will be assessed using uni- and multivariate correlation analysis. these novel studies will determine whether hypersecretion of adipocytokines by ia versus sc adipose tissue induces ir in patients with severe obesity.

Eligibility criteria:
inclusion criteria: enrolled in weight treatment program at emory bariatrics exclusion criteria: male smoker

Keywords: adipose tissue adipocytokines
a study of obinutuzumab, rituximab, polatuzumab vedotin, and venetoclax in relapsed or refractory follicular lymphoma (fl) or diffuse large b-cell lymphoma (dlbcl)

Conditions: Non-Hodgkin's Lymphoma

Summary: this study will evaluate the safety, efficacy, and pharmacokinetics of induction treatment with obinutuzumab, polatuzumab vedotin, and venetoclax in participants with relapsed or refractory fl, and with rituximab, polatuzumab vedotin, and venetoclax in participants with dlbcl. participants with fl who achieve complete response (cr), partial response (pr), or stable disease (sd) at the end of induction therapy will receive post-induction treatment with obinutuzumab and venetoclax, and participants with dlbcl who achieve cr or pr at the end of induction (eoi) will receive post-induction treatment with rituximab and venetoclax.


Eligibility criteria:
inclusion criteria: * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * for obinutuzumab + polatuzumab vedotin + venetoclax treatment group, relapsed or refractory fl after treatment with at least one prior chemoimmunotherapy regimen that included an anti-cluster of differentiation 20 (cd20) (anti-cd20) monoclonal antibody (mab) and for which no other more appropriate treatment option exists, as determined by the investigator * for rituximab + polatuzumab vedotin + venetoclax treatment group, relapsed or refractory dlbcl after treatment with at least one prior chemoimmunotherapy regimen that included an anti-cd20 mab and for which no curative option exists as determined by the investigator * at least one bidimensionally measurable lesion exclusion criteria: * known cd20-negative status at relapse or progression * prior allogeneic stem cell transplantation (sct), or autologous sct within 100 days prior to day 1 of cycle 1 * grade 3b fl * history of transformation of indolent disease to dlbcl * current use of systemic corticosteroids greater than (\>) 20 mg prednisone per day (or equivalent); or prior anti-cancer therapy to include: radioimmunoconjugate within 12 weeks; mab or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to day 1 of cycle 1 * central nervous system (cns) disease * active infection * actual or potential cytochrome p450 (cyp) 3a interactions including: requirement for warfarin; use of strong and moderate cyp3a inhibitors or inducers within 7 days prior to first dose of venetoclax; or consumption of grapefruit, seville oranges, or star fruit within 3 days prior to first dose of venetoclax * positive for human immunodeficiency virus (hiv) or hepatitis b or c * receipt of a live virus vaccine within 28 days prior to day 1 of cycle 1 * poor hematologic, renal, or hepatic function * pregnant or lactating women * life expectancy \<3 months
effectiveness of supportive psychotherapy through internet-based teleconsultation on psychological and somatic symptoms, neutrophil-lymphocyte ratio, and heart rate variability in post covid-19 syndrome patients

Conditions: Post-COVID-19 Syndrome

Summary: the goal of this clinical trial is to learn about the effectiveness of supportive psychotherapy in post covid-19 syndrome patients. the main questions it aims to answer are: 1. what is the effect of supportive psychotherapy on psychological and somatic symptoms in post covid-19 syndrome patients? 2. what is the effect of supportive psychotherapy on the neutrophil lymphocyte ratio in post covid-19 syndrome patients? 3. what is the effect of supportive psychotherapy on heart rate variability in post covid-19 syndrome patients? participants will be given supportive psychotherapy in the form of an online group for 3 times a week with a duration of psychotherapy ranging from 1 - 2 hours per session. researchers will compare the supportive psychotherapy group to education group as control. the control group will be given education about post covid-19 syndrome in the form of an online group for 3 times a week with a duration of around 1 - 2 hours per session.


Eligibility criteria:
inclusion criteria: * age 18 years or over * patients confirmed positive for sars cov-2 by molecular testing (sars cov-2 rt-pcr, naso-oropharyngeal swab) at least 3 months before recruitment, with symptoms and effects lasting for at least 2 months and not explained by alternative diagnoses other * patients with or without comorbidities: diabetes mellitus, hypertension, tuberculosis, asthma, chronic obstructive pulmonary disease, chronic kidney disease, heart disease, chronic liver disease, malignancy, nervous system disease, patients with vulnerability, patients with disabilities. * patients can communicate and are willing to be interviewed, fill out questionnaires and psychotherapy. * the patient is willing to fill out and sign an informed 1 sheet of consent to participate in the study exclusion criteria: * psychosis * can not access internet for psychotherapy * not willing to take part in the research
pemf effects on pain after abdominal body contouring

Conditions: Abdominal Body Contouring Surgery; Postoperative Pain

Summary: body contouring surgery has a higher potential for postoperative pain and wound healing complications. the purpose of this study is to determine if pulsed electromagnetic field (pemf) devices can reduce the pain and complications associated with this type of surgery. pulsed electromagnetic field (pemf) devices have been shown to be effective treatments to decrease healing time in nonunion fractures and pressure ulcers, and to reduce pain in whiplash injuries, persistent neck pain, and chronic lower back pain. these devices have been fda approved for treatment of pain and edema (510(k) number: k070541). more recently, pemf devices have been shown to decrease postoperative pain and narcotic use in breast augmentation patients. this study seeks to determine if pemf will also cause similar effects in the more complex procedures performed on body contouring patients. the specific aims of this study are: 1. evaluate if adjunct pemf therapy will accelerate the rate of postoperative pain reduction in abdominal body contouring patients. 2. evaluate if adjunct pemf therapy will decrease the postoperative use of narcotic pain relievers in abdominal body contouring patients. pemf devices have been shown to be effective in reduction of pain and pain medication use in breast augmentation patients. no literature has shown if pemf is an effective adjunct to decrease pain or pain medication use in the abdominal body contouring patient. a decrease in pain would result in a better experience for patients and a reduction in pain medication may decrease complications associated with these medications. the pemf therapy device being used in this study is a non-significant risk device because it is noninvasive and does not present a potential for serious risk to the health, safety, or welfare of a subject.


Eligibility criteria:
inclusion criteria: * age: 18 years and older and able to provide informed consent * eligible for and have agreed to be scheduled for elective abdominal body contouring surgery * willing and able to comply with all study procedures. exclusion criteria: * inability to provide informed consent * patients having multiple procedures concurrently except liposuction. * current use of oral steroids as determined through patient history and medical record review * current narcotic use as determined through patient history or medical record review * current nerve or pain disorder. * recent (1 month) coronary stent or implanted medical device (e.g. pacemaker). * pregnancy (demonstrated by a positive result of a urine pregnancy test) * based upon surgeon judgement and the results of screening procedures, patient is not a suitable candidate for surgery.
effects of seaweed extract on mental performance following a high-carbohydrate meal

Conditions: Cognitive Change

Summary: the current study will explore the impact of seaweed extract on cognitive function following a high-carbohydrate meal at a number of time-points post-consumption.

the current randomised, placebo-controlled, double-blind, parallel groups study will examine the impact of a brown seaweed extract (insea2) on cognitive function post-prandially in 60 healthy non-elderly adults who self-report post-meal drowsiness. computerised measures of episodic memory, attention and subjective state will be completed at baseline and for 3 hours following lunch with either seaweed or placebo consumed 30 minutes prior to a carbohydrate-rich meal.

Eligibility criteria:
inclusion criteria: * report post-meal drowsiness exclusion criteria: below 18 or above 65 years old at the time of giving consent * do not report post-meal drowsiness * any pre-existing medical condition/illness * history of/current head trauma * history of intestinal tract surgery * history of/current diagnosis of drug/alcohol abuse * currently taking prescription medications (excluding the contraceptive pill) * habitual use of dietary/herbal supplements * learning difficulties, adhd (attention deficit hyperactivity disorder), dyslexia * frequent migraines that require medication more than once/month. * visual impairment that cannot be corrected with glasses or contact lenses * smoking * excessive use of caffeine (\>500mg per day) from all dietary sources * not a native english speaker * food intolerances/sensitivities, including seafood/fish allergy * pregnancy, seeking to become pregnant, or current lactation * bmi \ 30 kg/m2 * any health condition that would prevent fulfilment of the study requirements * inability to complete all of the study assessments

Keywords: post-prandial cognition brown seaweed
assessment of biomarkers and cardiorenal syndrome in acute decompensated heart failure with vasodilator therapy

Conditions: Acute Decompensated Heart Failure

Summary: the purpose of this study is to determine whether nesiritide is more effective than nitroglycerin in modifying inflammatory and neurohormonal biomarkers without renal toxicity when proper infusion duration is administered.

no additional details provided

Eligibility criteria:
inclusion criteria: * at least 18 years of age. * subject must be able to understand the potential risks and benefits associated with the study. * baseline systolic blood pressure ≥ 90 mm hg at the time of enrollment. * clinical symptoms of dyspnea and laboratory admission bnp levels \> 500 pg/ml. * neither pregnant or breastfeeding at the time of enrollment. * authorization of patient's enrollment by patient's medical provider. exclusion criteria: * \<18 years of age * denies written informed consent * pregnant or lactating. * baseline systolic bp \< 90 mmhg or cardiogenic shock * no symptoms of congestion or admission bnp \< 500 pg/ml * known allergy to e.coli-derived products, or any history of anaphylactic reactions to nesiritide. * receiving dialysis at the time of enrollment. * serum creatinine \> 2.5 mg/dl at the time of enrollment.

Keywords: natriuretic peptides bnp heart failure nitoglycerin biomarkers
a study of bonviva (ibandronate) once monthly in post-menopausal women with osteopenia

Conditions: Post-Menopausal Osteopenia

Summary: this 2 arm study will evaluate the efficacy and safety of oral bonviva 150mg once monthly compared with placebo in post-menopausal women with osteopenia. patients will be randomized to receive either bonviva 150mg po monthly, or placebo monthly. the anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * women 45-60 years of age; * post-menopausal; * ambulatory. exclusion criteria: * vertebral fracture (except traumatic fracture such as in a motor vehicle accident); * low-trauma osteoporotic fracture in any other bone; * breast cancer diagnosed within last 20 years; * other malignancy diagnosed within last 10 years, except successfully resected basal cell cancer; * treatment with any bisphosphonate within last 2 years; * treatment with other drugs affecting bone metabolism within last 6 months.
comparison of igel and thrive on bronchoscopic interventions

Conditions: Lung Diseases; Total Intravenous Anesthesia; Tracheal Diseases

Summary: thrive and igel were applied for maintain oxygenation in bronchoscopic interventions which could not performed with an endotracheal tube. however, besides the risk of desaturation, the differences on difficulties to approach vocal cords, the responses to spay of local anesthetics including cough or spasm, the co2 elimination, the hemodynamic changes, and the effects on postoperative recovery are rarely investigated.

thrive and igel were applied for maintain oxygenation in bronchoscopic interventions which could not performed with an endotracheal tube. unlike the nasal cannula with thrive, the tips of igel are located in upper esophagi, it may affect the postoperative swallowing, especially for the aged group. however, the bronchoscopic approach may be easier for an established route to vocal cords. with shared airway for ventilation and interventions, co2 elimination is hardly monitored besides the risk of desaturation. in this study, thrive or igel was planned to be randomized used for bronchoscopic interventions in an adult group (age 20-65) and an aged group (age over 65). the difficulties to approach vocal cords, the responses to spay of local anesthetics including cough or spasm, the co2 elimination, the hemodynamic changes, and the effects on postoperative recovery are compared between thrive and igel groups.

Eligibility criteria:
inclusion criteria: * plan to receive bronchoscopic interventions with total intravenous anesthesia exclusion criteria: * awake bronchoscopy pregnancy